Nemolizumab
- Generic Name
- Nemolizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1476039-58-3
- Unique Ingredient Identifier
- GN465U8B72
- Background
Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 192
- Registration Number
- NCT05405985
- Locations
- 🇺🇸
Galderma Investigational Site 7024, Tempe, Arizona, United States
🇺🇸Galderma Investigational Site 7023, Lincoln, Nebraska, United States
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Phase 2
Completed
- Conditions
- Chronic Kidney Disease Associated Moderate to Severe Pruritus
- Interventions
- Drug: NemolizumabDrug: Placebo
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 258
- Registration Number
- NCT05075408
- Locations
- 🇺🇸
Galderma Investigational Site 9965, Miami, Florida, United States
🇺🇸Galderma Investigational Site7016, Miami, Florida, United States
🇺🇸Galderma Investigational Site 9962, Las Vegas, Nevada, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath